These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27561921)

  • 1. Medical Care Costs Associated With Long-term Weight Maintenance Versus Weight Gain Among Patients With Type 2 Diabetes.
    Nichols GA; Bell K; Kimes TM; O'Keeffe-Rosetti M
    Diabetes Care; 2016 Nov; 39(11):1981-1986. PubMed ID: 27561921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
    Yu AP; Wu EQ; Birnbaum HG; Emani S; Fay M; Pohl G; Wintle M; Yang E; Oglesby A
    Curr Med Res Opin; 2007 Sep; 23(9):2157-69. PubMed ID: 17669232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility of Laparoscopic Roux-en-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes and Obesity with a BMI ≥ 27.5 kg/m2: a Multi-Center Study with a 4-Year Follow-Up of Surgical Cohort.
    Tu Y; Wang L; Wei L; Xu Y; Han X; Han J; Yu H; Zheng C; Bao Y; Jia W
    Obes Surg; 2019 Dec; 29(12):3978-3986. PubMed ID: 31338737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of an Interprofessional Glycemic Optimization Clinic on Preoperative Glycated Hemoglobin Levels for Adult Patients With Type 2 Diabetes Undergoing Bariatric Surgery.
    Houlden RL; Yen JL; Moore S
    Can J Diabetes; 2018 Oct; 42(5):514-519. PubMed ID: 29530392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic implications of weight change in patients with type 2 diabetes mellitus.
    Bell K; Parasuraman S; Shah M; Raju A; Graham J; Lamerato L; D'Souza A
    Am J Manag Care; 2014 Aug; 20(8):e320-9. PubMed ID: 25295795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B
    Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study.
    Shantha GP; Kumar AA; Kahan S; Cheskin LJ
    Diabetes Educ; 2012; 38(3):417-26. PubMed ID: 22508341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden.
    Sabale U; Bodegard J; Svennblad B; Östgren CJ; Johansson G; Ekman M; Henriksson M; Nilsson P
    Prim Care Diabetes; 2017 Jun; 11(3):217-225. PubMed ID: 28389199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine.
    Buse JB; Wolffenbuttel BH; Herman WH; Hippler S; Martin SA; Jiang HH; Shenouda SK; Fahrbach JL
    Diabetes Care; 2011 Feb; 34(2):249-55. PubMed ID: 21270182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.
    Durden E; Lenhart G; Lopez-Gonzalez L; Hammer M; Langer J
    J Med Econ; 2016; 19(4):403-13. PubMed ID: 26653068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
    Fonseca V; McDuffie R; Calles J; Cohen RM; Feeney P; Feinglos M; Gerstein HC; Ismail-Beigi F; Morgan TM; Pop-Busui R; Riddle MC;
    Diabetes Care; 2013 Aug; 36(8):2162-8. PubMed ID: 23412077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
    Buysman EK; Liu F; Hammer M; Langer J
    Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting.
    McAdam-Marx C; Bouchard J; Aagren M; Nelson R; Brixner D
    Diabetes Obes Metab; 2010 Jan; 12(1):54-64. PubMed ID: 19758356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
    Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
    Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight change, blood pressure, lipids and glycemic control among patients with type 2 diabetes.
    Janghorbani M; Amini M; Salehi-Marzijarani M
    Ann Nutr Metab; 2011; 58(2):141-9. PubMed ID: 21613784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
    DeKoven M; Lee WC; Bouchard J; Massoudi M; Langer J
    Adv Ther; 2014 Feb; 31(2):202-16. PubMed ID: 24477354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with weight gain in people with type 2 diabetes starting on insulin.
    Balkau B; Home PD; Vincent M; Marre M; Freemantle N
    Diabetes Care; 2014 Aug; 37(8):2108-13. PubMed ID: 24824546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.